3.3. Primary Endpoint
A new relative decline in GLS by >15% from the baseline was found in nine patients (19%). Two (9.5%) were assigned to ivabradine and seven (26%) to control group (In the ivabradine group, GLS has not significantly changed from the baseline. In contrast, a significant decrease in GLS was observed in the control group after four AC cycles and at 6 months follow-up compared to baseline (